Aytu BioPharma shareholders approve 300,000-share increase to equity plan; all directors reelected

AYTU BIOPHARMA, INC

Shareholders approved Plan Amendment raising shares reserved under 2023 Equity Plan from 200,000 to 500,000 (increase of 300,000).
All five incumbent directors reelected: Disbrow, Donofrio, Dockery, Jain, Liu; each received majority vote.
Ratification of Grant Thornton LLP as auditor for fiscal 2025 approved with 4.12M for, 134k against.
Non-binding advisory vote on executive compensation passed with 2.39M for, 268k against.
Quorum of 70% (4.33M shares) present at May 21, 2025 annual meeting.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.